Marisa Wexler, MS, senior science writer —

Two previously-unknown mutations in the CLN5 gene were reported to cause CLN5 disease, a form of late infantile Batten disease, in a new study. The study also represents the second-ever publication describing CLN5 disease in people in Pakistan, hinting at a more worldwide distribution of the condition than…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Amicus Therapeutics‘ AT-GTX-502, an investigational gene therapy for Batten disease caused by mutations in the CLN3 gene, the company announced in a press release. This designation is given to investigational therapies that…

Polaryx Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) to open a clinical trial into PLX-200 as a potential treatment for juvenile Batten disease. Juvenile Batten, also known as Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) or CLN3 disease, is caused by mutations in…

An investigational gene therapy for late infantile (CLN2) Batten disease showed a good safety profile in a small clinical trial. The gene therapy also slowed the progression of the disease, though not to the extent of current standard-of-care treatment. Researchers are now working on more effective ways to deliver…